4//SEC Filing
Davis Robert E 4
Accession 0001209191-19-002955
CIK 0001567514other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 9:16 PM ET
Size
12.5 KB
Accession
0001209191-19-002955
Insider Transaction Report
Form 4
Davis Robert E
SVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2019-01-04$11.80/sh−2,702$31,884→ 43,989 total - Sale
Common Stock
2019-01-04$11.33/sh−6,862$77,746→ 46,691 total - Award
Restricted Stock Units
2019-01-08+54,988→ 54,988 total→ Common Stock (54,988 underlying) - Award
Stock Option (right to buy)
2019-01-08+75,554→ 75,554 totalExercise: $12.73Exp: 2029-01-07→ Common Stock (75,554 underlying)
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2018. The proceeds from these sales will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.77 to $11.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.78 to $11.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]On January 8, 2019, the reporting person was granted options to purchase 75,554 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- [F5]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F6]On January 8, 2019, the reporting person was granted 54,988 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Documents
Issuer
Intra-Cellular Therapies, Inc.
CIK 0001567514
Entity typeother
Related Parties
1- filerCIK 0001291959
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 9:16 PM ET
- Size
- 12.5 KB